Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 4/2021

01-11-2021 | COVID-19 | Original Article

Chemotherapy in the Covid-19 era: the patient’s perception

Authors: Maeve A. Hennessy, Anna Linehan, Darren Cowzer, Zachary L. Coyne, Orla Fitzpatrick, Fiona Barrett, Roisin Ni Dhonaill, Bryan T. Hennessy, Liam Grogan, Patrick G. Morris, Oscar S. Breathnach

Published in: Irish Journal of Medical Science (1971 -) | Issue 4/2021

Login to get access

Abstract

Background

The Covid-19 pandemic poses significant challenges for the management of patients with cancer. In our institution, we adapted our delivery of outpatient systemic anti-cancer therapy (SACT) by introducing a number of ‘risk-reducing’ measures including pre-assessment screening.

Aims

We sought to evaluate the experience and perceptions of patients with cancer undergoing SACT during the Covid-19 pandemic.

Methods

Patients on SACT during the Covid-19 pandemic were eligible for participation. Data were collected by anonymous survey over a 1 week period during the most intensive phase of government restrictions. Patients were asked questions under three headings: perceived risk of infection exposure, changes to treatment plan and psychological impact of Covid-19.

Results

One hundred patients were assessed, 60% were male, 41% were > 65 years of age and 67% had advanced cancer. Eleven percent of patients were living alone. Fifty-seven percent reported feeling at increased risk in general of contracting Covid-19. Sixty-eight percent of patients did not feel worried about contracting Covid-19 in the hospital. Ninety-two percent of patients reported wanting to continue on SACT as originally planned. Fifty-eighty percent felt isolated and 40% reported increased anxiety.

Conclusion

Though patients on active treatment for cancer during the Covid-19 pandemic reported increased anxiety and feelings of isolation due to Covid-19, the majority of patients wanted to continue SACT as originally planned. Patients would benefit from enhanced psycho-oncological supports in the event of a prolonged Covid-19 pandemic.
Literature
2.
go back to reference Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Oncol 395:1054–1062CrossRef Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Oncol 395:1054–1062CrossRef
3.
go back to reference Liang W, Guan W, Chen R et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020 21(3):335–337CrossRef Liang W, Guan W, Chen R et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020 21(3):335–337CrossRef
13.
go back to reference Jazieh AR, Chan SL, Curigliano G et al (2020) Delivering cancer care during the COVID-19 pandemic: recommendations and lessons learned from ASCO global webinars. JCO Global Oncol 2020(6):1461–1471CrossRef Jazieh AR, Chan SL, Curigliano G et al (2020) Delivering cancer care during the COVID-19 pandemic: recommendations and lessons learned from ASCO global webinars. JCO Global Oncol 2020(6):1461–1471CrossRef
15.
go back to reference Conte P, Frassoldati A, Bisagni G et al (2018) Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol 29:2328–2333 Medline, Google ScholarCrossRef Conte P, Frassoldati A, Bisagni G et al (2018) Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol 29:2328–2333 Medline, Google ScholarCrossRef
16.
go back to reference Earl HM, Hiller L, Vallier A-L et al (2019) 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 393:2599–2612CrossRef Earl HM, Hiller L, Vallier A-L et al (2019) 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 393:2599–2612CrossRef
17.
go back to reference Guo Y, Xiong B-H, Zhang T, Cheng Y et al (2016) XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Investig 34:94–104CrossRef Guo Y, Xiong B-H, Zhang T, Cheng Y et al (2016) XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Investig 34:94–104CrossRef
20.
go back to reference Brooks SK, Webster RK, Smith LE et al (2020) The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet Oncol. 2020 Mar 14 395(10227):912–920CrossRef Brooks SK, Webster RK, Smith LE et al (2020) The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet Oncol. 2020 Mar 14 395(10227):912–920CrossRef
Metadata
Title
Chemotherapy in the Covid-19 era: the patient’s perception
Authors
Maeve A. Hennessy
Anna Linehan
Darren Cowzer
Zachary L. Coyne
Orla Fitzpatrick
Fiona Barrett
Roisin Ni Dhonaill
Bryan T. Hennessy
Liam Grogan
Patrick G. Morris
Oscar S. Breathnach
Publication date
01-11-2021
Publisher
Springer International Publishing
Published in
Irish Journal of Medical Science (1971 -) / Issue 4/2021
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-020-02457-3

Other articles of this Issue 4/2021

Irish Journal of Medical Science (1971 -) 4/2021 Go to the issue

Letter to the Editor

The reality of sex

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine